Danish biotech company Adcendo ApS announced on Wednesday that it will be presenting data on its two novel antibody-drug conjugate (ADC) programs ADCE-T02, targeting Tissue Factor, and ADCE-D01, targeting urokinase plasminogen activator receptor-associated protein (uPARAP), at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois.

Adcendo says that ADCE-T02 is a potential best-in-class Topo-1 inhibitor-based ADC targeting Tissue Factor (TF). Tissue Factor is clinically validated target overexpressed in a broad range of solid tumours, with limited expression in normal tissues. ADCE-T02 shows strong anti-tumour activity in a wide range of solid tumour models and is well tolerated in non-human primate toxicology studies with no evidence of toxicity from earlier generation TF ADCs. A phase 1 clinical trial in advanced solid tumours is ongoing in both Australia and the United States.

Regarding ADCE-D01, Adcendo says that it is a first-in-class ADC targeting uPARAP conjugated to the Topo-1 inhibitor payload P-1021. uPARAP is a novel endocytic ADC target that is overexpressed in tumours of mesenchymal origin, such as sarcomas, while exhibiting restricted expression in normal tissues. ADCE-D01 is composed of a first-in-class uPARAP-targeting antibody conjugated to an optimised, clinically validated linker payload technology, selected for its superior efficacy and tolerability. Preclinically, ADCE-D01 shows strong anti-tumour activity in a range of mesenchymal tumour models, including soft tissue sarcoma, and is well tolerated in non-human primate toxicology studies with a favourable safety profile and no evidence of target-specific toxicity. A phase 1 clinical trial in advanced soft tissue sarcomas is enrolling in the United States and is under regulatory review in the European Union.